Derik De Bruin
Stock Analyst at B of A Securities
(4.96)
# 19
Out of 4,842 analysts
210
Total ratings
65.03%
Success rate
85.82%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $4.32 | +154.63% | 13 | Mar 3, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $72 → $65 | $58.08 | +11.91% | 7 | Feb 20, 2025 | |
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $7.42 | +115.63% | 5 | Feb 19, 2025 | |
| WAT Waters | Maintains: Neutral | $430 → $410 | $354.59 | +15.63% | 13 | Feb 13, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $156 | $110.88 | +40.69% | 32 | Jan 27, 2025 | |
| RVTY Revvity | Upgrades: Buy | $138 | $91.35 | +51.07% | 2 | Dec 13, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $675 → $660 | $402.13 | +64.13% | 18 | Dec 13, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $235 | $138.78 | +69.33% | 3 | Dec 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $220 → $210 | $136.25 | +54.13% | 5 | Dec 13, 2024 | |
| WST West Pharmaceutical Services | Maintains: Buy | $350 → $355 | $211.39 | +67.94% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $23.19 | +12.12% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $247.03 | +9.70% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $171.38 | +6.20% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $36.96 | +116.45% | 12 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $189.01 | +53.43% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $24.50 | -38.76% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $4.18 | +402.39% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $25 | $8.86 | +182.17% | 8 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $21.52 | +48.70% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $84.43 | +18.44% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $63.71 | +34.99% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.96 | +228.28% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,157.50 | +31.75% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.01 | +223.38% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $130.84 | +98.72% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $7.42 | +1,517.25% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 | $44.38 | +41.03% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $165.40 | -27.45% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $1.57 | +473.25% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $514.06 | -54.29% | 3 | Nov 2, 2018 |
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $4.32
Upside: +154.63%
Exact Sciences
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $58.08
Upside: +11.91%
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $7.42
Upside: +115.63%
Waters
Feb 13, 2025
Maintains: Neutral
Price Target: $430 → $410
Current: $354.59
Upside: +15.63%
Agilent Technologies
Jan 27, 2025
Maintains: Neutral
Price Target: $150 → $156
Current: $110.88
Upside: +40.69%
Revvity
Dec 13, 2024
Upgrades: Buy
Price Target: $138
Current: $91.35
Upside: +51.07%
Thermo Fisher Scientific
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $402.13
Upside: +64.13%
IQVIA Holdings
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $138.78
Upside: +69.33%
Charles River Laboratories International
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $136.25
Upside: +54.13%
West Pharmaceutical Services
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $211.39
Upside: +67.94%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $23.19
Upside: +12.12%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $247.03
Upside: +9.70%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $171.38
Upside: +6.20%
Dec 13, 2024
Maintains: Buy
Price Target: $78 → $80
Current: $36.96
Upside: +116.45%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $189.01
Upside: +53.43%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $24.50
Upside: -38.76%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $4.18
Upside: +402.39%
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $8.86
Upside: +182.17%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $21.52
Upside: +48.70%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $84.43
Upside: +18.44%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $63.71
Upside: +34.99%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.96
Upside: +228.28%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,157.50
Upside: +31.75%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.01
Upside: +223.38%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $130.84
Upside: +98.72%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $7.42
Upside: +1,517.25%
Oct 6, 2020
Upgrades: Buy
Price Target: $63
Current: $44.38
Upside: +41.03%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $165.40
Upside: -27.45%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $1.57
Upside: +473.25%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $514.06
Upside: -54.29%